Patrick Hoversten

Patrick Hoversten

Auto-generated profile, based on publicly available information

Patrick Hoversten

Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
KWKimberly N Weaver
Kimberly N Weaver
MGMartin Gregory
Martin Gregory
GSGaurav Syal
Gaurav Syal
PHPatrick Hoversten
Patrick Hoversten
SHStephen Bradley Hicks
Stephen Bradley Hicks
EBEdward L Barnes
Edward L Barnes
Crohn’s disease (CD) of the pouch and chronic pouchitis occur in approximately 10% of patients after ileal pouch–anal anastomosis (IPAA) for refractory ulcerative colitis (UC) or UC-related dysplasia. The efficacy of anti–tumor necrosis factor (anti-TNF) agents and vedolizumab have been reported for the treatment of CD of the pouch and chronic pouchitis, but little is known regarding the use of ustekinumab in these settings. Our primary aim was to evaluate the efficacy of ustekinumab for these conditions. This is a retrospective, multicenter cohort study evaluating the efficacy of ustekinumab in patients with CD of the pouch and chronic pouchitis. Clinical response or remission was judged by the treating physician’s assessment at 6 months. Fifty-six patients (47 with CD of the pouch and 9 with chronic pouchitis) were included the study. Of these, 73% had previously been treated with either anti-TNF therapy, vedolizumab, or both after IPAA. Among patients with CD of the pouch and chronic pouchitis, 83% demonstrated clinical response 6 months after induction with ustekinumab. Responders demonstrated significantly less pouch inflammation on endoscopy when compared with nonresponders (29% vs 100%; P = 0.023). Higher mean body mass index at induction (26.3 vs 23.7; P = 0.033) and male sex (83% vs 30%; P = 0.014) were significant predictors of nonresponse to ustekinumab in those with CD of the pouch. In this refractory patient population, ustekinumab appears to be a safe and effective treatment for chronic pouchitis and CD of the pouch in biologic-naïve patients and those with prior anti-TNF or vedolizumab therapy failure.

27 February 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
MGMartin Gregory
Martin Gregory
KWKimberly N Weaver
Kimberly N Weaver
PHPatrick Hoversten
Patrick Hoversten
SHStephen Bradley Hicks
Stephen Bradley Hicks
DPDevin Patel
Devin Patel
PDParakkal Deepak
Parakkal Deepak
Background and Aims: Inflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn’s disease (CD) of the pouch and chronic antibiotic-dependent or antibiotic-refractory pouchitis. Methods: This was a retrospective, multicenter cohort study at 5 academic referral centers in the United States. Adult patients with endoscopic inflammation of the pouch who received vedolizumab were included. The primary outcome was clinical response at any time point. Secondary outcomes included clinical remission, endoscopic response, and remission. Univariate analysis and multivariate analysis were performed for the effect of the following variables on clinical response: fistula, onset of pouchitis less than 1 year after IPAA, younger than 35 years old, gender, previous tumor necrosis factor inhibitor-alpha use, and BMI >30. Results: Eighty-three patients were treated with vedolizumab for inflammation of the pouch between January 2014 and October 2017. Median follow-up was 1.3 years (interquartile range 0.7–2.1). The proportion of patients that achieved at least a clinical response was 71.1%, with 19.3% achieving clinical remission. Of the 74 patients with a follow-up pouchoscopy, the proportion of patients with endoscopic response and mucosal healing was 54.1% and 17.6%, respectively. Patients who developed pouchitis symptoms less than 1 year after undergoing IPAA were less likely to respond to vedolizumab, even after controlling for other risk factors. Conclusions: Vedolizumab is safe and effective in the management of CD of the pouch and chronic pouchitis. Further studies are needed to compare vedolizumab with other biologic therapies for pouchitis and CD of the pouch.

8 October 2018 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
PHP Hoversten
P Hoversten
AKA K Kamboj
A K Kamboj
DKD A Katzka
D A Katzka
Infectious esophagitis is a leading cause of esophagitis worldwide. While esophageal infections have traditionally been associated with immunocompromised patients, these disorders are becoming increasingly recognized in immunocompetent individuals. The three most common etiologies of infectious esophagitis are Candida, herpes simplex virus, and cytomegalovirus. Human papilloma virus infection can also involve the esophagus in the form of ulcerative lesions and papillomas. Less common etiologies include various other fungal, bacterial, and viral organisms. This review provides a comprehensive update on risk factors, diagnosis, and management of both common and less common infections of the esophagus.

1 January 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PHPatrick Hoversten
Patrick Hoversten
FOFouad Otaki
Fouad Otaki
DKDavid A. Katzka
David A. Katzka

1 March 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PHPatrick Hoversten
Patrick Hoversten
AKAmrit K. Kamboj
Amrit K. Kamboj
TWTsung-Teh Wu
Tsung-Teh Wu
DKDavid A. Katzka
David A. Katzka

17 April 2018 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
PHPatrick Hoversten
Patrick Hoversten
JBJoel Beachey
Joel Beachey
MPMichael Pham
Michael Pham
ABAnjali Bhagra
Anjali Bhagra
A 33-year-old man presented with new-onset, asymmetric, migratory oligoarthritis in the setting of several weeks of nausea and vomiting, diarrhoea, fevers and dysuria. He was initially treated in the inpatient setting with broad-spectrum antibiotics due to concern for an evolving sepsis presentation. Arthrocentesis of a large right knee effusion revealed inflammatory synovial fluid without findings suggestive of septic arthritis. Human leucocyte antigen B27 was positive and, taken together with the antecedent history of gastroenteritis, dysuria and inflammatory oligoarthritis, the clinical diagnosis was most consistent with reactive arthritis. Antibiotics were discontinued. His treatment course proved refractory to non-steroidal anti-inflammatory drugs and intra-articular and systemic glucocorticoid therapy with concurrent use of sulfasalazine and ultimately necessitated treatment with a tumour necrosis factor alpha inhibitor.